A multicenter double blind, placebo-controlled study to evaluate the safety and efficacy of MEM 1003 for the treatment of patients with bipolar I disorder suffering acute manic or mixed episodes

Trial Profile

A multicenter double blind, placebo-controlled study to evaluate the safety and efficacy of MEM 1003 for the treatment of patients with bipolar I disorder suffering acute manic or mixed episodes

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2008

At a glance

  • Drugs MEM 1003 (Primary)
  • Indications Bipolar disorders; Bipolar I disorders; Mania
  • Focus Therapeutic Use
  • Sponsors Memory Pharmaceuticals
  • Most Recent Events

    • 05 May 2008 Actual number of patients enrolled was 60 according to the clinicaltrials.gov record.
    • 05 May 2008 The actual completion date for this trial is Mar 2007 according to the clinialtrials.gov record.
    • 07 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top